Description du projet
Innovation dans le diagnostic des maladies cardiovasculaires
Les maladies cardiovasculaires sont responsables de 1,9 million de décès chaque année dans l’UE, ce qui en fait l’une des causes de décès les plus fréquentes. Le projet Wirecath, financé par l’UE, vise à financer, valider cliniquement et fournir un dispositif médical innovant pour le diagnostic des maladies du myocarde et du rétrécissement des artères coronaires. Cette technologie offre une grande précision, un meilleur rapport coût-efficacité et une plus grande maniabilité. Elle repose sur une base solide et non complexe qui utilise un nouveau positionnement des capteurs de pression réduisant le risque d’erreurs hydrostatiques qui conduiraient habituellement à un diagnostic évaluant mal l’intensité de la maladie.
Objectif
Cavis Technologies has an objective to clinically validate and commercialise Wirecath – its novel medical device for assessing severity of narrowings in the coronary arteries and myocardial disease. It has the potential to substantially reduce management costs in cardiovascular disease by improving its diagnosis, and thus, increasing opportunity for timely prevention of disease progression and its severe complications, such as angina, shortness of breath and heart attack.
Wirecath has several premium features over competing solutions. These are an unique high accuracy, superior manoeuvrability and cost-effectiveness. Its simple and robust design bases on a unique position of pressure sensor and resistance to hydrostatic error, that standard pressure wires are liable to. Given that hydrostatic error often leads to misdiagnosis of the coronary artery disease severity, Wirecath optimises diagnostic accuracy and offers long-lasting benefits to patients, cardiologists and healthcare providers.
The unique accuracy allow new methods to be developed, applicable to another large patient group that has non-obstructive CAD, with no good diagnosis tools available today.
With this project, Cavis intends to support 2019’s commercial launch of Wirecath and plan further product development and large-scale clinical
evaluation studies that will follow the first-in-man study planned for 2019. Cavis’ current research and development activities are supported by
investment from shareholders and numerous innovation grants. Cavis plans to apply for SME Instrument Phase 2 funding to perform clinical studies that will build trust in its unique features and increase its commercial value.
With 1.9 million deaths a year, cardiovascular diseases are the leading cause of death in the EU and place a considerable burden on healthcare
systems and government budgets. Prevention and treatment of various cardiovascular diseases, is of a high strategic priority.
Champ scientifique
Programme(s)
Régime de financement
SME-1 - SME instrument phase 1Coordinateur
753 23 UPPSALA
Suède
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.